Natera Inc. alleges that Inivata Ltd.‘s cancer detection and monitoring products including RaDar infringe a patent issued Tuesday covering methods for sequencing and analyzing cell-free DNA from the blood.
Inivata, which like co-defendant Inivata Inc. is a subsidiary of NeoGenomics Inc., began selling the RaDar minimum residual disease assay in the US in late April 2021 through NeoGenomics and through Agendia Inc., Inivata’s strategic commercialization partner in the US, according to a complaint filed later the same day in the US District Court for the District of Delaware.
Cambridge, England-based Inivata Ltd.—a direct competitor of Natera in ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.